The Safety, Tolerability and Efficacy of NouvNeu001 for Parkinson's Disease
The Safety, Tolerability and Efficacy of NouvNeu001 for Parkinson's Disease
Recruiting · NCT06167681 · Registry updated 2024-11-01Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| The Safety, Tolerability and Efficacy of NouvNeu001 for Parkinson's Disease | Parkinson disease, basal ganglia disorder, brain disorder, central nervous system disorder, movement disorder, nervous system disorder, neurodegenerative disease, parkinsonian disorder, synucleinopathy | Recruiting | Phase 1 / Phase 2 | 2024-11-01 | NCT06167681 |
1 results · Page 1 of 1
Organizations
Swipe the table sideways for more columns.
| Organizations | Linked trials |
|---|---|
| iRegene Therapeutics Co., Ltd. | 8 |
2 results · Page 1 of 1
Research sites
Swipe the table sideways for more columns.
| Research sites | City | Country | Linked trials |
|---|---|---|---|
| Beijing Hospital | Beijing | China | 33 |
| Zhongnan Hospital of Wuhan University | Wuhan | China | 65 |